Amgen, Watson Pharmaceuticals, Abbott, Sigma-Aldrich and BioCryst - People on the move

By Anna Lewcock

- Last updated on GMT

Related tags Senior vice president Pharmaceutical companies of the united states Management occupations Amgen

Amgen, Watson Pharmaceuticals, Abbott, Sigma-Aldrich and BioCryst
have all had people on the move in the world of pharmaceutical

Following Dennis Fenton's​ decision to retire form his role as vice president of operations, senior vice president of manufacturing Fabrizio Bonanni​ will be stepping up to take over the role at biotech behemoth, Amgen​. Fenton leaves after 25 years with the company, joining the firm in its early days and now one of its longest serving staff. Bonanni has been senior vice president of manufacturing at the company since 2003, overseeing the company's site operations and contract manufacturing. Prior to joining Amgen, Bonanni held senior position at Baxter International. Madhu Balachandran will take over Bonanni's former role, currently at Amgen's Puerto Rico operations. Watson Pharmaceuticals​ has also recently announced a change at the top, with current chairman, president and CEO Allen Chao​ planning to retire at the beginning of September. Chao will remain as chairman of the board for the forseeable future, also assuming the role of executive chairman from September 4 through until the end of the year. Chao will be succeeded Paul Bisaro​, current president and chief operating officer of Barr Pharmaceuticals, who has been named CEO effective September 4. Yet another retirement has been announced over the last week, with Abbott's​ chief operating officer Richard Gonzalez​ stepping down after 30 years with the company. Gonzalez will remain with the firm until the end of September, after which the heads of the company's businesses will report directly to the CEO, Miles White. Sigma-Aldrich​ has also lost a board member this week, with Nina Fedoroff​ resigning to become science and technology adviser to the US secretary of state, Condoleeza Rice. Fedoroff was nominated for the role by the National Academy of Sciences, and will serve a three year term in the position. Elliott Berger​ has been appointed senior vice president of regulatory affairs for novel therapeutics firm BioCryst Pharmaceuticals​. Berger previously held senior quality and regulatory positions at EMD Pharmaceuticals (a subsidiary of Merck KGaA), Astra pharmaceuticals and Merck Research laboratories.

Related topics Markets & Regulations

Related news

Show more

Follow us


View more